Antenatal lamivudine to reduce perinatal hepatitis B transmission: a cost-effectiveness analysis

Nayeri UA, Werner EF, Han CS, Pettker CM, Funai EF, Thung SF

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1016/j.ajog.2012.06.001

Original Paper URL

Indexing Status
Subject indexing assigned by NLM

MeSH
Cost-Benefit Analysis; Decision Support Techniques; Disease Transmission, Infectious /economics /prevention & control; Female; Hepatitis B, Chronic /economics /prevention & control /transmission; Humans; Lamivudine /economics /therapeutic use; Pregnancy; Reverse Transcriptase Inhibitors /economics /therapeutic use

AccessionNumber
22012033817

Date bibliographic record published
08/02/2013